GLP-1 r ett sdant inkretinhormon, och GIP r ett annat
Patients who value FDA-approved drugs and closer medical supervision will likely feel more confident with a more clinically intensive program
Public awareness of GLP-1 drugs has increased in the past year, with about one-third (32%) of adults now saying they have heard a lot about these drugs, up from 19% in July 2023
Clinical trial data from the STEP and SURMOUNT programs demonstrate that maximum weight loss typically occurs between 60-72 weeks of treatment, with most patients losing 1-2 pounds per week during the active weight loss phase
This approach could enable initial treatment with highly effective but expensive GLP-1 agonists, followed by maintenance with more affordable alternatives
CagriSema CagriSema r en kombination av cagrilintide (en syntetisk version av det kroppsegna hormonet amylin, som minskar aptit och hungersknslor i hjrnan) och semaglutid (som gr p GLP-1 -receptorer, samma substans som i Wegovy och Ozempic)
